News Home

Is it Time to Dump Inhibrx Inc (INBX) Stock After it Is Higher By 73.76% in a Week?

Wednesday, October 05, 2022 10:14 AM | InvestorsObserver Analysts
Is it Time to Dump Inhibrx Inc (INBX) Stock After it Is Higher By 73.76% in a Week?

Overall market sentiment has been high on Inhibrx Inc (INBX) stock lately. INBX receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Inhibrx Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on INBX!

What is Stock Sentiment?

Sentiment is a very short-term indicator that is entirely technical. There is no information about the health of profitability of the underlying company in our sentiment score. As a technical indicator, news about the stock, or company, such as an earnings release or other event, could move the stock counter to the recent trend. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With INBX Stock Today?

Inhibrx Inc (INBX) stock is higher by 1.01% while the S&P 500 is down -1.4% as of 9:59 AM on Wednesday, Oct 5. INBX is higher by $0.30 from the previous closing price of $29.76 on volume of 84,793 shares. Over the past year the S&P 500 is down -13.08% while INBX is down -3.47%. INBX lost -$2.86 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Inhibrx Inc click here.

More About Inhibrx Inc

Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates. It combines an understanding of target biology with protein engineering, proprietary discovery technologies, and an integrative approach to research and development to design differentiated therapeutic candidates. The company has four programs in clinical trials, of which three of the programs are for the treatment of various cancers, and one for the treatment of Alpha-1 Antitrypsin Deficiency. Click Here to get the full Stock Report for Inhibrx Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App